Yu-Hui Liu

Dr. Yu-Hui Liu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2021 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
YLYu-Hui Liu
Yu-Hui Liu
YWYe-Ran Wang
Ye-Ran Wang
QWQing-Hua Wang
Qing-Hua Wang
YCYang Chen
Yang Chen
XCXian Chen
Xian Chen
YWYanjiang Wang
Yanjiang Wang
Background: Understanding the long-term effects of coronavirus disease 2019 (COVID-19) on cognitive function is essential for monitoring the cognitive decline in the elderly population. This study aims to assess the current cognitive status and the longitudinal cognitive decline in elderly patients recovered from COVID-19. Methods: This cross-sectional study recruited 1539 COVID-19 inpatients aged over 60 years who were discharged from three COVID-19-designated hospitals in Wuhan, China, from February 10 to April 10, 2020. In total, 466 uninfected spouses of COVID-19 patients were selected as controls. The current cognitive status was assessed using a Chinese version of the Telephone Interview of Cognitive Status-40 (TICS-40) and the longitudinal cognitive decline was assessed using an Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Cognitive assessments were performed 6 months after patient discharge. Results: Compared with controls, COVID-19 patients had lower TICS-40 scores and higher IQCODE scores [TICS-40 median (IQR): 29 (25 to 32) vs. 30 (26 to 33), p < 0.001; IQCODE median (IQR): 3.19 (3.00 to 3.63) vs. 3.06 (3.00 to 3.38), p < 0.001]. Severe COVID-19 patients had lower TICS-40 scores and higher IQCODE scores than non-severe COVID-19 patients [TICS-40 median (IQR): 24 (18 to 28) vs. 30 (26 to 33), p < 0.001; IQCODE median (IQR): 3.63 (3.13 to 4.31) vs. 3.13 (3.00 to 3.56), p < 0.001] and controls [TICS-40 median (IQR): 24 (18 to 28) vs. 30 (26 to 33), p < 0.001; IQCODE median (IQR) 3.63 (3.13 to 4.31) vs. 3.06 (3.00 to 3.38), p < 0.001]. Severe COVID-19 patients had a higher proportion of cases with current cognitive impairment and longitudinal cognitive decline than non-severe COVID-19 patients [dementia: 25 (10.50 %) vs. 9 (0.69 %), p < 0.001; Mild cognitive impairment (MCI): 60 (25.21 %) vs. 63 (4.84 %), p < 0.001] and controls [dementia: 25 (10.50 %) vs. 0 (0 %), p < 0.001; MCI: 60 (25.21 %) vs. 20 (4.29 %), p < 0.001)]. COVID-19 severity, delirium and COPD were risk factors of current cognitive impairment. Low education level, severe COVID-19, delirium, hypertension and COPD were risk factors of longitudinal cognitive decline. Conclusions: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased risk of long-term cognitive decline in elderly population. COVID-19 patients, especially severe patients, should be intensively monitored for post-infection cognitive decline.

1 September 2020 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
YCY. Cen
Y. Cen
XCX. Chen
X. Chen
YSY. Shen
Y. Shen
XZX.-H. Zhang
X.-H. Zhang
YLY. Lei
Y. Lei
YLYu-Hui Liu
Yu-Hui Liu

3 August 2018 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
JWJun Wang
Jun Wang
WJWang-Sheng Jin
Wang-Sheng Jin
XBXian-Le Bu
Xian-Le Bu
FZFan Zeng
Fan Zeng
ZHZhi-Lin Huang
Zhi-Lin Huang
YWYanjiang Wang
Yanjiang Wang

31 May 2024 in Science Advances
Verified
Journal Article
Open access
PSPu-Yang Sun
Pu-Yang Sun
JLJie Liu
Jie Liu
JHJian-Ni Hu
Jian-Ni Hu
YTYun-Feng Tu
Yun-Feng Tu
QJQiu Jiang
Qiu Jiang
JWJun Wang
Jun Wang
Immunosenescence contributes to systematic aging and plays a role in the pathogenesis of Alzheimer’s disease (AD). Therefore, the objective of this study was to investigate the potential of immune rejuvenation as a therapeutic strategy for AD. To achieve this, the immune systems of aged APP/PS1 mice were rejuvenated through young bone marrow transplantation (BMT). Single-cell RNA sequencing revealed that young BMT restored the expression of aging- and AD-related genes in multiple cell types within blood immune cells. The level of circulating senescence-associated secretory phenotype proteins was decreased following young BMT. Notably, young BMT resulted in a significant reduction in cerebral Aβ plaque burden, neuronal degeneration, neuroinflammation, and improvement of behavioral deficits in aged APP/PS1 mice. The ameliorated cerebral amyloidosis was associated with an enhanced Aβ clearance of peripheral monocytes. In conclusion, our study provides evidence that immune system rejuvenation represents a promising therapeutic approach for AD.

1 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
YLYu-Hui Liu
Yu-Hui Liu
JWJun Wang
Jun Wang
QLQiao-Xin Li
Qiao-Xin Li
CFChristopher J. Fowler
Christopher J. Fowler
FZFan Zeng
Fan Zeng
YWYanjiang Wang
Yanjiang Wang
NAbs to different epitopes of Aβ are differentially associated with the severity and progression of Alzheimer’s disease.

28 August 2015 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
YLYu-Hui Liu
Yu-Hui Liu
XBXian-Le Bu
Xian-Le Bu
CLChun-Rong Liang
Chun-Rong Liang
YWYe-Ran Wang
Ye-Ran Wang
TZTao Zhang
Tao Zhang
YWYanjiang Wang
Yanjiang Wang
Senile plaques consisting of amyloid-beta (Aβ) are the major pathological hallmark of Alzheimer’s disease (AD) and have been the primary therapeutic target. Immunotherapies, which are designed to remove brain Aβ deposits, increased levels of soluble Aβ and accelerated brain atrophy in some clinical trials, suggesting that the solubilization of Aβ deposition might facilitate the formation of more toxic Aβ oligomers and enhance neurotoxicity. The capacity of antibodies against different epitopes of Aβ to disaggregate preformed Aβ fibrils was investigated. The co-incubation of antibodies and Aβ fibrils was then tested for neurotoxicity both in vitro and in vivo. After the incubation of preformed Aβ fibrils with the N-terminal antibody 6E10, the fibrils were decreased, while the oligomers, mostly dimers and trimers, were significantly increased. However, no such effects were observed for antibodies targeting the middle domain (4G8) and C-terminus of Aβ (8G7). The co-incubates of preformed Aβ fibrils with 6E10 were more neurotoxic, both in vitro and in vivo, than the co-incubates with 4G8 and 8G7. Our results indicate that the antibody targeting the N-terminus of Aβ promoted the transformation of Aβ from fibrils into oligomers and increased neurotoxicity. Immunotherapies should take into consideration the enhanced neurotoxicity associated with the solubilization of Aβ deposits by antibodies against the Nterminus of Aβ.